© 2023 MJH Life Sciences and Urology Times. All rights reserved.
© 2023 MJH Life Sciences™ and Urology Times. All rights reserved.
September 30th 2022
Expert perspectives on the risk of cardiovascular disease as it exists in the context of androgen deprivation therapy (ADT) and prostate cancer.
Shared insight on a timeline of clinical studies contextualizing cardiovascular disease in the setting of prostate cancer management.
Comprehensive insight regarding strategies to mitigate cardiovascular risk in patients on therapy for prostate cancer.
December 8th 2022
Centering focus on a patient case of cardiovascular risk and prostate cancer, experts share their perspective on management strategies.